← Back to Clinical Trials
Recruiting NCT07151183

Diagnosis, Prognosis, and Mechanisms in Panvascular Disease

Trial Parameters

Condition Panvascular Diseases
Sponsor Jinwei Tian
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2024-12-01
Completion 2030-12-31
Interventions
No intervention

Brief Summary

This study aims to establish a standardized cohort for panvascular diseases, encompassing biological materials such as DNA samples, along with extensive patient medical records and follow-up information. The design of this database will enable it to serve as a comprehensive resource for future medical research. Upon data collection, researchers will conduct various statistical analyses to enhance our understanding of the factors and mechanisms contributing to various panvascular diseases, including coronary heart disease, myocardial infarction, stroke, and peripheral vascular disease. These statistical analyses will also aid in identifying more effective treatment strategies for these conditions. By amassing a large volume of data from a significant number of patients with panvascular diseases, researchers will be able to perform highly precise analyses of the factors influencing the onset, progression, and treatment of these diseases. The results of these precise analyses can then be utilized to optimize clinical practices for the prevention and treatment of panvascular diseases.

Eligibility Criteria

Inclusion Criteria: 1. Male or female aged 18 to 80 years old; 2. Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries; 3. Voluntary participation in this study and provision of signed informed consent. Exclusion Criteria: 1. Severe hemodynamic instability; 2. Severe cardiac dysfunction (EF \< 30%); 3. Severe arrhythmias; 4. Severe valvular heart disease; 5. Cardiomyopathy caused by non-coronary artery diseases; 6. Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.); 7. Severe non-cardiovascular diseases; 8. Women who are pregnant or breastfeeding; 9. Individuals who refuse to provide signed informed consent.

Related Trials